Acute graft-versus-host disease (aGVHD) is a major complication after allogeneic bone marrow transplantation (allo-BMT), and infiltration of donor leukocytes into aGVHD target organs is partially orchestrated by chemokines. Using a murine BMT model, the expression of 30 chemokines or chemokine receptors in the lung, liver, gut and tongue was analyzed using real-time PCR at 1, 2, 3 and 6 weeks after BMT during the development of clinical aGVHD and target organ histopathology. CXCL9-11 expression was linked to elevated expression of CXCR3 in the gut, lung and tongue. In contrast, hepatic CXCR3 expression was not changed, whereas a clear association was seen for CXCL16 and CXCR6 expression. An elevated intestinal CCL3 expression 1 week after allo-BMT was associated with an increased expression of CCR5 but not CCR1 or CCR3, and in the lung and liver CCL3-CCL5 expression was associated with increases in CCR1 and CCR5. Overexpression of CCL2, CCL8, CCL12 and their receptor CCR2 was found in the liver and lung, but not in the gut and tongue. On the basis of the differences in kinetics and organ distribution, more studies are required to better characterize specific targets within this network, as this will allow the development of novel preventive and therapeutic approaches by using single or multiple targeting reagents.
Introduction
Allogeneic bone marrow transplantation (allo-BMT) often presents the only curative treatment for a number of malignant and non-malignant diseases. 1 However, its utility is limited by the development of severe treatmentrelated complications, most importantly, the occurrence of acute graft-versus-host disease (aGVHD). The pathophysiology of aGVHD is complex and can be divided into three phases as follows: (1) conditioning toxicity to host tissue, leading to the secretion of inflammatory cytokines and enhanced allo-stimulatory capacity of host antigen-presenting cells (APCs); (2) induction of donor T-cell activation and T-cell expansion; and (3) cellular effector phase, during which activated T cells are recruited into target organs and cause severe tissue injury. 2 Chemokines comprise a family of proteins predominantly between 8 to 14 kDa, which at this point can be divided into four different subgroups: CC group (CCL1-28), CXC group (CXCL1-16), C group (XCL1-2) and CX3C group (CX3CL1). 3, 4 They exert their effects through the interaction with one or more members of a family of seven-transmembrane domain-containing G proteincoupled receptors. 5, 6 Chemokine expression can be enhanced by inflammatory cytokines, 7 and chemokines have an important role in recruiting cells of the innate and adaptive immune system to the sites of inflammation. [8] [9] [10] Furthermore, they can have additional functions in the context of leukocyte activation, 11 angiogenesis, 12, 13 hematopoiesis 14 and organization or function of secondary lymphoid tissues. [15] [16] [17] The chemokine-chemokine receptor system shows high complexity and redundancy with more than one chemokine binding to one receptor and multiple receptors interacting with one chemokine. Increased expression of a number of chemokines and chemokine receptors in GVHD target organs has been described earlier, [18] [19] [20] [21] and previous studies have further shown that targeting one specific chemokine or chemokine receptor can result in the reduction of aGVHDrelated injury to various target organs. 11, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Interestingly, tropism and efficacy of such a strategy differed depending on the chemokine and/or the chemokine receptor involved, 33 suggesting that the enhanced expression of chemokines after allo-BMT may differ between organs with respect to quality, quantity and kinetics.
In this study, we analyzed chemokine and chemokine receptor expression patterns in GVHD target organs using a well-established murine BMT model, in which alloreactivity occurs across MHC (major histocompatibility complex) class I, MHC class II and minor histocompatibility antigen mismatches. Degree and kinetics of the expression of 16 chemokines and 14 chemokine receptors were analyzed in the lung, liver, gastrointestinal (GI) tract and tongue and were correlated with systemic inflammation and histopathological organ changes.
Results

Development of aGVHD after allo-BMT
To assess mRNA expression profiles of chemokines and chemokine receptors in aGVHD target organs, a wellestablished murine BMT model was used for GVHD induction. Lethally irradiated B6D2F1 (H-2 bxd ) mice received 5 Â 10 6 bone marrow cells supplemented with 10 Â 10 6 splenocytes from either syngeneic (B6D2F1) or allogeneic (C57BL/6; H-2 b ) donors. Syngeneic recipients showed minor changes in weight, fur texture and mobility because of radiation toxicity at week 1, which was followed by complete clinical recovery after BMT (Figures 1a and b) . In contrast, allogeneic recipients developed severe clinical aGVHD within the first week after BMT in parallel to systemic inflammation (Figures 1c and d) and early T-cell expansion. 34, 35 During this period, prominent histopathological changes were already seen in the GI tract, whereas injury to other aGVHD target organs such as the liver, lung and skin was only of minor severity and extent (Figure 1e ), reflecting the combined damaging effects of conditioning toxicity and inflammatory cytokines, such as tumor necrosis factor-a (TNFa) and interferon-g (IFNg), on the GI tract. Subsequently, subsiding levels of serum TNFa and IFNg indicated a decrease in systemic inflammation in allogeneic recipients, but clinical recovery was only partial and temporary, and was observed before progressive clinical symptoms along with increasing target organ injury to the gut, liver, lung and skin developed. 2 As shown for the lung, liver and gut, the immunohistochemical detection of CD3 þ T cells in aGVHD target organs showed progressive T-cell infiltration from week 1 to week 3 in aGVHD target organs of animals receiving allo-BMT, confirming the migratory effects of donor T cells to target organs during the cellular effector phase of aGVHD (Figure 1f) .
Expression of the IFNg-inducible chemokines, CXCL9-11, and CXCR3 Interferon-g levels have been correlated with aGVHD severity, but whether this correlation implies a deleterious role of IFNg in GVHD development, reflects only the presence of large numbers of activated T cells or may even prove beneficial for distinct organ injury is not completely understood. [36] [37] [38] [39] [40] We analyzed the expression of the IFNg-inducible chemokines, CXCL9-11, [41] [42] [43] and their receptor CXCR3 in GVHD target organs. RNA was isolated from organs at weeks 1, 2, 3 and 6 after syngeneic or allogeneic BMT as described in Materials and methods, and gene expression was determined using real-time reverse transcription (RT)-PCR. The tongue was used as an equivalent for skin GVHD based on earlier studies showing comparable kinetics of lymphocytic infiltration and epithelial cell apoptosis between the tongue and the ear skin tissue as well as based on the presence of rete-like prominences of the squamous epithelium of the murine dorsal tongue, which are similar to rete ridges in the human epidermis but are absent in the murine epidermis and may present possible primary sites of injury. [44] [45] [46] CXCL9-11 and CXCR3 expression was increased early in all four target organs after allo-BMT (Figure 2) and  correlated with systemic IFNg and TNFa levels (Supplementary Table S1 ). CXCL9 expression was highest in the tongue, followed by the lung, GI tract and liver, and as shown for the liver and gut, mRNA expression levels reflected increased protein expression levels at individual time points (Figure 7) . Except for the lung, in which maximum expression occurred at week 2, CXCL9 expression peaked in all other target organs at 1 week after allo-BMT and then declined (Figure 2b ). CXCL10 expression was also at its maximum early after allo-BMT in the tongue, followed by the lung and liver, and then in each organ the expression decreased over time, remaining significantly higher in allogeneic recipients than in syngeneic controls (Figure 2b ). In the gut, no significant changes were seen. A similar time course of expression was seen for CXCL11 in the lung, tongue and liver, and similar to CXCL9, CXCL11 expression was significantly upregulated in the gut at any time point after allo-BMT.
CXCL9-11 mediate the recruitment of CXCR3 þ leukocytes to inflammatory sites. [47] [48] [49] Interestingly, except for the liver, CXCR3 expression was significantly increased in all other target organs at any time. It was highest at week 1 and then decreased by week 2, followed by a second increase in the GI tract and tongue, but not in the lung until week 6. Supported by the correlation analysis (Supplementary Table S1 ), these findings suggest that early IFNg expression and TNFa are two major factors for inducing these chemokines at this time point, leading to the initial recruitment of CXCR3 þ T cells as shown earlier for the lung. 24 In addition, the CXCL9-11:CXCR3 interactions may have only a minor role in the recruitment of CXCR3 þ T cells to the liver, and at later time points, the recruitment of CXCR3-expressing T cells to other target organs may be mediated not only by CXCL9-11 but also independently from these ligands through other axes in the chemokinechemokine network.
Expression of CCL3-5 chemokines and CCR1, CCR3 and CCR5 CCL3-5 chemokines are expressed by various cell types including T and natural killer (NK) cells, endothelial and epithelial cells, fibroblasts, neutrophils and APCs. They can be induced in response to inflammatory stimuli such as TNFa and IFNg; 9 and in this study, a close correlation between their expression and systemic cytokine levels was seen (Supplementary Table S2 ). CCL3-5 chemokines bind to (among others) CCR1, CCR3 and CCR5, which are expressed on T cells, NK cells, macrophages and dendritic cells.
33
CCL3 expression was significantly increased in all four organs after allo-BMT and at any time point when compared with syngeneic controls (Figure 3) . Interestingly, in the GI tract and tongue, CCL3 expression was highest at week 1 after BMT and then decreased, whereas in the liver and lung, it constantly increased from week 1 to week 3. CCL4 expression in the GI tract was not significantly changed, and similar to CCL3, it was significantly increased in the tongue, liver and lung, was assessed by histopathology at weeks 1, 3 and 6 after BMT using a semiquantitative scoring system as described in Materials and methods. (f) CD3 þ immunohistochemistry (brown stain) of the liver, lung, GI tract and skin from syngeneic and allogeneic animals was carried out at weeks 1 and 3 after allo-BMT. Data are presented as mean ± s.e.m. and are from one representative experiment of two similar transplantations, syngeneic (n ¼ 4 at each time point) and allogeneic (n ¼ 4-7 at each time point); *Po0.05 and **Po0.01. peaking at around week 2 to week 3 after allo-BMT. CCL5 expression levels were highest at week 1 only in the tongue and then constantly decreased over time. Expression kinetics in the liver and lung were similar to those of CCL3 and CCL4, reaching maximum levels in the liver by week 3 and in the lung by week 2. CCL3 protein levels did not only directly correlate with respect to their changed kinetics when compared with mRNA expression levels but were also significantly increased in the liver and the GI tract at 1 and 3 weeks after allo-BMT, and CCL5 showed a similar expression kinetics on both the mRNA and the protein levels at these time points (Figure 7) .
We then analyzed the expression of CCR1, CCR3 and CCR5 to determine whether upregulation of their ligands is associated with increased receptor expression in individual target organs of aGVHD. CCR3 expression in organs of animals after allo-BMT was not statistically different from the CCR3 organ expression in naive animals or in syngeneic recipients (Supplementary  Tables S6-S9) , and despite a strong upregulation of CCL3, CCL4 and CCL5 in the tongue, no significant changes were seen for CCR1 or CCR5 expression. These findings suggest that CCR3 expression, in general, may not be directly associated with organ involvement during aGVHD, and that for the development of mucocutaneous aGVHD, chemokine receptors other than CCR1 and CCR5 have a more critical role. In the gut, CCR1 expression was not changed for the first 2 weeks and then showed a slight but significant increase at weeks 3 and 6, whereas in the liver and lung, it was already high at week 1 and stayed at the same level until week 3 and week 2, respectively. CCR5 expression was increased early in the GI tract at week 1 after allo-BMT, decreased at week 2 and then increased from week 3 until week 6 in parallel to CCR1 expression. In the liver, CCR5 expression increased over the first 3 weeks after allo-BMT, and in the lung, it was increased only at week 2. It is reasonable to assume that, although early CCL3 expression in the gut, which has been previously shown to be host-cell-dependent, 50 correlates with increased GI CCR5, but not CCR1 expression (Supplementary Table  S2 ), CCL4 and CCL5 may contribute to the gut GVHD to a much lesser extent during this period. Changes in CCL3, CCL4 and CCL5 expression observed later coincide with increased CCR1 and CCR5 expression in all organs, most likely reflecting the recruitment of CCR1-and CCR5-expressing leukocytes, 11,31,50,51 which themselves are capable of producing CCL3 and CCL5 as a mechanism of positive reinforcement for effector cell recruitment to organ sites. 50 Supportive of these findings, a correlation was found for CCR5 and, to a lesser extent, for CCR1 with target organ pathology at both early (the gut and skin) and later (the gut, skin, liver and lung) time points after allogeneic BMT (Supplementary Table S2 ).
Expression of CXCL16 and CXCR6
CXCL16 is expressed in both lymphoid and nonlymphoid tissues 33, [52] [53] [54] and binds to the T-cell-expressed receptor, CXCR6, regulating cell migration both to the thymus and to inflammatory sites. 9 After BMT, differences in CXCL16 expression between syngeneic and allogeneic recipients were seen in the liver and GI tract, but not in the lung and tongue (Figure 4a ). Hepatic CXCL16 expression was significantly increased between weeks 1 and 3, and then decreased again. In the GI tract, CXCL16 expression was not different early between syngeneic and allogeneic recipients, but then constantly increased in allogeneic recipients until week 6.
Despite no increase in expression of its ligand, CXCL16, was seen in the lung, CXCR6 was highly expressed in this organ as early as 1 week after allo-BMT, followed by a continuous decrease. In the liver, the expression of CXCR6 paralleled the expression of CXCL16. In the GI tract, CXCR6 expression was strongly elevated at week 1, temporarily declined and then, along with rising ligand expression levels, it increased again until week 6. No statistical differences in CXCR6 expression were seen in the tongue after syngeneic versus allogenic BMT.
Expression of XCL1 and XCR1 XCL1 belongs to the C chemokine family and is produced by different cell types, including mast cells, 33 activated CD4 þ and CD8 þ T cells, [55] [56] [57] [58] and NK cells. 59 Its receptor, XCR1, is expressed on T cells, NK cells, neutrophils and B cells. 33 After BMT, XCL1 expression levels significantly differed between syngeneic and allogeneic recipients in all four organs (Figure 4b ), whereas the upregulation 6 bone marrow cells supplemented with 10 Â 10 6 splenocytes from either syngeneic (B6D2F1, white bar) or allogeneic (C57BL/6, black bar) donors. Expression levels of CCL3-5, CCR1 and CCR5 were determined in GVHD target organs by real-time PCR at week 1, 2, 3 and 6 after BMT. Data are combined from two independent experiments and presented as mean±s.e.m.; syngeneic (n ¼ 4-8 at each time point); allogeneic (n ¼ 7-14 at each time point) animals; *Po0.05 and **Po0.01.
of XCR1 was only seen after allo-BMT in the liver and lung.
Intestinal XCL1 expression started to increase 1 week after allo-BMT and constantly increased until week 6. In contrast, XCL1 expression peaked in the tongue at week 1 and then decreased from week 2 to week 6, and similarly, in the lung it was increased between week 1 and week 2, before decreasing until week 6. In the liver, it was elevated between week 1 and week 3, and then returned to syngeneic levels at week 6. Differences in XCR1 expression between syngeneic and allogeneic recipients were less evident. In correlation with XCL1 expression, both in the liver and in the lung XCR1 expressions were increased by week 2 (Supplementary  Table S3 ) and then decreased during week 3 to week 6.
Expression of CCL2, CCL8, CCL12 and CCR2
In addition to CCL8 and CCL12, CCL2 is the major ligand of CCR2, and interactions between CCL2 and CCR2 have been shown in earlier studies to be critically involved in T-cell and monocyte/macrophage migration to GVHD target organs including the lung. 25, 29 CCL2, CCL8 and CCL12 expression increased in the lung as early as 1 week after allo-BMT, peaked by week 2 and then rapidly declined ( Figure 5 ). In the liver, peak expression of CCL2 and CCL12 was seen at week 1 after allo-BMT, followed by a constant decrease until week 6, when expression of neither of these two chemokines differed from syngeneic controls. No significant changes in expression were seen for CCL8 in the liver, for CCL2, CCL8 and CCL12 in the GI tract, and for CCL2 and CCL12 in the tongue at any time point, the latter organ showing significant increases only for CCL8 at weeks 2 and 3 after allo-BMT. Early upregulation of CCL2 and CCL12 in the liver and of CCL2, CCL8 and CCL12 in the lung after allo-BMT was associated with a delayed increase in CCR2 expression levels in these organs, which reached maximum values around Figure 4 mRNA expression of CXCL16, CXCR6, XCL1 and XCR1. Lethally irradiated B6D2F1 mice received 5 Â 10 6 bone marrow cells supplemented with 10 Â 10 6 splenocytes from either syngeneic (B6D2F1, white bar) or allogeneic (C57BL/6, black bar) donors. (a) Expression levels of CXCL16 and CXCR6 and of (b) XCL1 and XCR1 were determined in GVHD target organs by real-time PCR at week 1, 2, 3 and 6 after allo-BMT. Data are combined from two independent experiments and presented as mean±s.e.m.; syngeneic (n ¼ 4-8 at each time point) and allogeneic (n ¼ 7-14 at each time point) animals; *Po0.05 and **Po0.01.
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A Bouazzaoui et al week 3 followed by a subsequent decrease, and was closely correlated with histopathology (Supplementary  Table S4 ).
Expression of CXCL1, CXCL2 and CXCR2 CXCL1 and CXCL2 belong to the CXC chemokine subfamily and are produced by endothelial cells, epithelial cells and APCs. 33 They have a direct role as chemoattractants for CXCR2-expressing neutrophils, 60, 61 but can also mediate T-cell recruitment through the induction of CXCL9 and CXCL10. 60 Except for the GI tract, CXCL1 expression was strongly increased between week 1 and week 2 after allo-BMT in all target organs (Figure 6a ) and correlated with inflammatory cytokine expression (Supplementary Table S5 ). Upregulation was highest in the liver, followed by the tongue and lung, and whereas expression in the latter two organs as well as in the GI tract did not differ from that of syngeneic controls at later time points, CXCL1 expression remained significantly elevated in the liver throughout the duration of the study and correlated with the severity of hepatic pathology (Supplementary Table S5 ). In addition, an association between increased mRNA levels and protein levels of CXCL1 expression was seen when tested for the liver and gut at 1 or 3 weeks after BMT (Figure 7) . No significant differences in CXCL2 expression between syngeneic and allogeneic recipients were seen in any organ, except for the lung at week 1. Interestingly, however, CXCL2 expression levels both in the GI tract and in the tongue were strongly elevated at 1 week after both syngeneic and allo-BMT, suggesting that the upregulation of CXCL2 expression at this time is rather related to radiation toxicity than to alloreactivity. In contrast to the early increase in ligand expression in the GI tract, tongue and lung, CXCR2 expression in these organs was not significantly increased (Figure 6a ). However, in the liver, in which extreme upregulation of CXCL1 expression was observed, CXCR2 mRNA levels were significantly elevated at weeks 2 and 3 in association with increased numbers of infiltrating neutrophils (Figures 6b and c) , and correlated with organ pathology at week 6 (Supplementary Table S5 ).
Early inflammation after allo-BMT induces the expression of inflammatory chemokines in the spleen Finally, we analyzed whether systemic inflammation early after allo-BMT also induces the expression of inflammatory chemokines in secondary lymphoid tissues such as the spleen. As expected, increased systemic levels of IFNg or TNFa led to enhanced expression of various inflammatory chemokines, including CXCL9-11, CCL3-5, CCL2, CCL8, CCL12 and XCL1 (Supplementary Table S10 ). However, no increases in the expression of the respective chemokine receptors, that is, Table S10 ), suggesting that cells expressing these receptors may rapidly leave secondary lymphoid tissues and migrate to classical GVHD target organs.
Discussion
Allogeneic bone marrow transplantation is an important therapy for many disorders affecting the hematopoietic and immune system. 1 However, its broader application is limited by the development of aGVHD. Soluble factors, such as cytokines and chemokines, regulate and promote the interactions of cellular components, such as T cells and APCs, and their recruitment to target sites. Two earlier studies 18, 19 on the expression of chemokines after allo-BMT focused on the first 10 days after allo-BMT, comparing the effects of lethal with those of nonmyeloablative conditioning, or described chemokine expression and T-cell infiltration in GVHD target organs of unconditioned SCID recipient mice, 18, 19 both studies considering only a small number of chemokines. Other studies, in which gene expression profiling after allo-BMT was carried out, included a high number of chemokines, but restricted their study to only one organ. 20, 62, 63 In our study, we analyzed the expression of chemokines and chemokine receptors in four major aGVHD target organs at four different time points during a time course of 6 weeks after allo-BMT in order to better understand the kinetics of chemokine expression in distinct target organs and their role in organ-specific aGVHD pathophysiology on the transcriptional level.
Inflammatory chemokines are expressed in inflamed tissues by both hematopoetic and non-hematopoetic cells upon stimulation by pro-inflammatory cytokines, including TNFa and IFNg. 64 We found that, except for GI CXCL10 and hepatic CXCR3 expression, increased systemic IFNg levels early after allo-BMT were generally associated with higher organ expression levels of the IFNg-inducible chemokines CXCL9-11 and of their receptor, CXCR3. After early peak expression, CXCL9-11 expression levels declined until week 6, whereas CXCR3 expression reached a second peak at 6 weeks again in the gut and tongue. In addition, the CXCR3 expression was not significantly altered in the liver at any time point after allo-BMT. These findings support previous reports on the expression of CXCR3 or its ligands during aGVHD 18, 21, 22, 24 and on the role of IFNg-CXCL9-11-regulated recruitment of CXCR3 þ T cells to aGVHD target organs. 22, 24, 28, 31 However, to what extent the IFNg-CXCL 9-112CXCR3 cascade contributes to the multi-facetted mechanism of leukocyte recruitment to specific GVHD target organs is not yet completely understood and may further depend on conditioning intensity 18, 31 or specific CXCR3 þ T-cell subsets being recruited. 39, 65 CXCR6 has been shown to be expressed on liverinfiltrating CD8 þ T cells after allo-BMT and to be functionally involved in the early recruitment of these cells to the liver, but not to the gut. 66, 67 Consistent with these findings, in this study, hepatic expression of both CXCR6 and its ligand, CXCL16, was strongly elevated from week 1 to week 3, supporting the concept that the migration of CXCR6 þ T cells to the liver in response to increased ligand expression is operative in aGVHD of the liver. Intestinal CXCL16 expression was not altered at 1 week after allo-BMT and then continuously increased from week 2 to week 6. In the lung, it was not increased at any time point. In contrast, intestinal and pulmonary CXCR6 expression was significantly elevated as early as 1 week after allo-BMT. As Ueha et al.
67 reported no effect of anti-CXCL16 treatment on intestinal GVHD within the first 2 weeks after BMT, it can be speculated that the CXCR6:CXCL16 interactions potentially contribute to Tcell infiltration of the intestine at later time points. Early CXCR6 expression in the absence of increased ligand expression instead may be due to co-expression of CXCR6 on T cells being recruited through other mechanisms. A similar phenomenon can be proposed for increased CXCR6 expression in the lung without any changes in CXCL16 expression.
Inflammatory chemokines of the CC, C or CXC3C families are also increasingly expressed after allo-BMT. 11, [25] [26] [27] 50, 68 As suggested by Wysocki et al., 32 cellular sources of chemokines may differ between specific target organs. Our results showing peak CCL3 expression in the gut and tongue early after allo-BMT, followed by a continuous decline, strengthen the concept that increased CCL3 production in these organs derives from host cells, 50 whereas in contrast, the observed increase in CCL3 expression in the liver and lung over the first 3 Figure 7 Chemokine expression is increased both on mRNA and on protein levels in aGVHD target organs after allogeneic BMT. Protein expression levels of CXCL1, CXCL9, CCL3 and CCL5 were determined in the liver and GI tract at 1 and 3 weeks after BMT as described in Materials and methods. Data are combined from two independent experiments and presented as mean ± s.e.m.; syngeneic (white): n ¼ 8 (week 1) or 7 (week 3); allogeneic (black): n ¼ 11 (week 1) or n ¼ 13 (week 3); **Po0.01.
weeks after allo-BMT may be dependent on the expression by infiltrating T cells. 50 Interestingly, expression levels of CCL4 and CCL5, which both share CCR5 as a receptor with CCL3, were not significantly elevated in the GI tract of allogeneic recipients. Also, in contrast to CCR5, CCR1 expression was not increased in the gut early after allo-BMT, suggesting that the CCL3:CCR5 interactions rather than CCL4, CCL5 or CCR1 are involved in the early recruitment of T cells to the GI tract. 32, 50, 51 In the tongue, CCL4 levels persisted highly elevated for the first 3 weeks after allo-BMT, whereas after an initial peak expression, CCL5 levels continuously decreased. In addition, despite the increased expression of their ligands, CCR1 and CCR5 levels were not elevated, suggesting that in this organ system other chemokines and chemokine receptors may mediate aGVHD-related injury. 69 Similar to CCL3, pulmonary and hepatic expression levels of CCL4 and CCL5 increased until weeks 2-3 and were associated with increased CCR1 and CCR5 expression. Previous reports indicated increased CCL3 and CCL5 expression by alloreactive T cells in the course of aGVHD development; 26, 50 hence it is likely that in addition to CCL3 50, 70 and CCL5 expression, 26 CCL4 production by infiltrating T cells potentially contributes to a chemokine-mediated feedback mechanism on the recruitment of CCR1 þ or CCR5 þ donor T cells to these organs.
The role of XCL1 (lymphotactin a) in the development of aGVHD has not yet been defined. Predominantly produced by activated Th1 CD4 þ , CD8 þ T cells and NK cells, 71, 72 XCL1 ligation to its receptor XCR1 not only induces T and NK cell recruitment and co-activates macrophages but also can increase regulatory T-cell function, suppress the IFNg production of CD4 þ T cells and seems to be involved in organ rejection. 71, [73] [74] [75] [76] [77] [78] Increased levels of XCL1 have been reported in the bronchoalveolar lavage fluid of mice suffering from idiopathic pneumonia syndrome after allogeneic BMT, 79 and antigen priming of CTLs was enhanced in the presence of XCL1. 80 Therefore, it can be speculated, that XCL1-XCR1 interactions can promote the inflammatory process of aGVHD through an autocrine or a paracrine pathway or potentially mediate a downregulation of inflammation through regulatory and tolerogenic effects.
In our study, increased expression levels of CCR2 were preceded by elevated CCL2 and CCL12 expression in the liver and lung and were associated with the observed kinetics of histopathological changes in these organs, whereas neither receptor nor ligand was significantly altered in the GI tract or tongue. Using the same haploidentical BMT model, a critical role of donor leukocyte expression of CCR2 has been shown for the development of pulmonary GVHD, 25 and in a fully mismatched BMT model, CCR2 expression of the host did not contribute to pulmonary dysfunction after allo-BMT. 81 Terwey et al. 29 reported the requirement of CCR2 expression on donor cells for intestinal and hepatic aGVHD, but not for cutaneous CD8 þ T-cell-mediated aGVHD. In CD4 þ T-cell-mediated hepatic aGVHD, CCR2 deficiency of donor T cells rather led to increased T-cell infiltrates. 82 Therefore, the exact role of CCR2 may differ in relation to the degree of MHC mismatch and a leukocyte subpopulation, and seems to vary between specific GVHD target organs.
The role of neutrophils in the development of aGVHD is not well understood. CXCR2 expression was only increased in the liver, and expression of its ligand CXCL1 was several fold stronger in the liver than in the lung and tongue, being associated with increased neutrophil infiltration. Therefore, the CXCL1:CXCR2-mediated recruitment of granulocytes potentially contributes to hepatic organ injury, 83, 84 and as CXCL1 has been further attributed an inductive role on the production of CXCL9-10 by T cells, 60 an indirect mechanism may exist to promote and perpetuate the development of aGVHD.
Many chemokines, such as CXCL9-11, CCL2, CCL8, CCL12, were highly expressed in parallel to systemic TNFa or IFNg protein levels and before the appearance of significant histopathological changes in individual aGVHD target organs. However, expression of others, for example, CCL3-CCL5 or XCL1, clearly coincided with the development of lymphocytic infiltrates in specific organs, supporting the hypothesis that chemokine induction in GVHD target organs after allo-BMT is prone to two major mechanisms: (1) 'ectopic' early inflammatory cytokine production as soluble mediators, leading to in situ chemokine expression in an endocrine manner 20 and (2) chemokine induction through infiltrating donor leukocytes within target organs in situ, contributing to a chemokine-mediated feedback mechanism on the recruitment of these cells. Furthermore, although the former mechanism most likely drives early aGVHD development, the possibility that specifically the latter mechanism, in addition to perpetuating local alloreactive injury, may be involved in suppressing prolonged and dysregulated inflammation during the later course of disease, and therefore may be partially responsible for decreased expression levels of many chemokines as observed at later time points as well cannot be excluded. 32, 73 Alloantigen presentation by host-and potentially donor-derived DCs with subsequent T-cell activation is a critical mechanism operative in the development of GVHD. For the activation and maturation of these cells, TNFa and induction of the nuclear transcription factor NF-kB are important, 85, 86 and in parallel to the decrease in these factors over time, DC maturation may not be completed, potentially leading to the inhibition and alteration of T-cell responses 87, 88 and co-contributing to the downregulation of chemokine expression at later time points.
In summary, our study shows the complexity of a consistently growing network of chemokines and chemokine receptors in the development of aGVHD. Future experimental studies, which will extend the current knowledge on specific chemokine-chemokine interactions and their role in the development of organ complications after allo-BMT, are needed to identify specific targets for novel preventive and therapeutic strategies against the tremendous clinical challenges of aGVHD initiation and progression.
Materials and methods
Mice and stem cell transplantation Female C57BL/6 (H-2 b ) and B6D2F1 (H-2 bxd ) mice were purchased from Charles River Laboratories (Sulzbach, Germany) and acclimatized in our animal facility for at least 1 week before the experiments. The animals were between 10 and 20 weeks at the time of BMT. All animal experiments were approved by the local institutional animal committee of the University of Regensburg and were in accordance with German Animal Protection Laws.
Naive, untreated mice were transplanted according to a standard protocol as described previously. 27 On the day of BMT, B6D2F1 recipient mice received lethal total body irradiation with a total dose of 13 Gy, delivered in two fractions 3 h apart to reduce GI toxicity, using a linear accelerator at 150 cGy min
À1
. Total body irradiation was followed by the infusion of cell mixtures of 5 Â 10 6 bone marrow cells supplemented with 10 Â 10 6 splenocytes from either syngeneic (B6D2F1) or allogeneic (C57BL/6) donors. Syngeneic and allogeneic groups were analyzed for chemokine and chemokine receptor expression levels and for GVHD target organ histopathology at weeks 1, 2, 3 and 6 after transplantation. Transplanted mice were housed in micro-isolator cages with autoclaved bedding and fed autoclaved chow and autoclaved or hyperchlorinated water.
Clinical GVHD and survival Survival was monitored daily until day þ 42 after BMT, and clinical GVHD scores were assessed weekly by a scoring system incorporating five clinical parameters, namely weight loss, posture (hunching), mobility, fur texture and skin integrity. 89 Each parameter was graded between 0 and 2. Once an animal reached a cumulative score of X6.5 or a weight loss of more than 35%, it was killed and counted as death due to transplantationrelated mortality.
Semiquantitative histopathology of the lung, liver, intestine and skin At weeks 1, 2, 3 and 6 after transplantation, animals were killed for histopathological analysis. Organs were removed, fixed in 4% paraformaldehyde dissolved in phosphate-buffered saline, transferred into 70% ethanol after 48 h, paraffin-embedded and then sectioned into 4-mm-thick slices. Hematoxylin-eosin-stained lung sections from individual mice were coded without reference to mouse type and prior treatment and independently examined by a pathologist to establish an index of GVHD injury. Detailed analysis of changes in the GI tract, liver and lung histology were carried out in a blinded manner at 1, 2, 3 and 6 weeks after transplantation as described earlier. [24] [25] [26] Histopathology of the skin was assessed at the same time points by grading the extent of epithelial cell apoptosis and lymphocellular infiltrates from 0 to 4 (none, mild, mild-moderate, moderate and severe). The numbers of neutrophils in the liver at weeks 1 and 3 was assessed by an independent pathologist in a semiquantitative and blinded manner and graded with 0 (normal), 2 (focal mild), 4 (diffuse mild) or 6 (diffuse severe). The analysis was carried out using light microscopy (Axioskop 2 plus, Carl Zeiss GmbH, Jena, Germany). Photographs of histopathology were obtained by AxioCam HRc (Carl Zeiss GmbH) and processed using AxioVision Release 4.6.3 (Carl Zeiss GmbH).
Lung, liver and gut chemokine analysis After exsanguination, the organs were harvested at 1 or 3 weeks after transplantation and immediately snapfrozen in liquid nitrogen. At the time of analysis, 70 mg of organ tissue was homogenized in 1 ml buffer solution (1 Â PBS and 1 tablet of Complete Protease Inhibitor Cocktail (Roche Diagnostics, Basel, Switzerland)), centrifuged at 1500 r.p.m. for 15 min at 4 1C, and the supernatant was harvested. Total protein concentration in the supernatant was determined using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA) before chemokines were measured by ELISA as described below. Chemokine concentration in the supernatant was normalized to picograms per milligram of total protein (pg per ml of total protein).
Measurements of IFNg and TNFa serum levels and chemokine levels in the liver and GI tract by ELISA Serum protein levels of IFNg and TNFa and of CCL3, CCL5, CXCL1 and CXCL9 in the liver and gut were measured by ELISA (IFNg and TNFa: OptEIA, BD Pharmingen, Heidelberg, Germany; CCL3, CCL5, CXCL1 and CXCL9: Quantikine M, R&D Systems, Wiesbaden, Germany). Assays were carried out according to the manufacturer's protocols.
Immunohistochemistry
For immunostaining, 4 mm of organ slices were dewaxed and re-hydrated, followed by incubation in 3% H 2 O 2 for 10 min to quench endogenous peroxidase activity. CD3 þ cells were then detected by rabbit IgG anti-mouse CD3 antibody (Sigma, St Louis, MO, USA) and by a goat-antirabbit IgG-HRP (horseradish peroxidase) secondary antibody (Dako, Hamburg, Germany). Immunoenzymatic reactions were carried out using HRP and stains were shown using 3,3 0 -diaminobenzidine (Dako). The slides were counterstained with hematoxylin.
Determination of organ mRNA expression levels using real-time PCR RNA RT. Total cellular RNA was extracted using RNeasy Mini Kits (Qiagen, Hilden, Germany) according to the manufacturer's protocol. First-strand cDNA was synthesized using 1 mg of total RNA (DNase-treated): 1 mg of total RNA in 8 ml of RNase-free water was denatured for 5 min at 75 1C, then 10 ml of RT reaction mixture (Invitrogen, Karlsruhe, Germany) and 2 ml of RT enzyme mixture (Invitrogen, Karlsruhe, Germany) were added. The RNA and RT mixture was incubated for 10 min at 25 1C, followed by 60 min at 44 1C and a denaturing step for 5 min at 85 1C. cDNA was stored at À20 1C until use for real-time PCR.
Real-time PCR. All real-time PCRs were carried out in a 10-ml mixture containing 4 ml of sample, 5 ml SYBR Green mix (Invitrogen, Karlsruhe, Germany), 0.25 ml of sense primer (10 mM), 0.25 ml of antisense primer (10 mM) and 0.5 ml water. Real-time PCR quantifications were carried out using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The fluorescence threshold value was calculated using the ABI PRISM 7900HT Sequence Detection System software (version SDS 2.2, Applied Biosystems). GAPDH was used as a reference. The primers used for real-time PCR are listed in Table 1 .
Statistical considerations
For statistical analysis, an algorithm of statistical tests was applied. First, we used analysis of variance (ANOVA) to test whether organ-specific expression levels of individual genes at any time point in animals after allo-BMT and in naive, untreated animals differed. The minimal level of confidence at which results were judged significant was Po0.05. Next, expression levels of those genes tested significant by ANOVA were compared between syngeneic and allogeneic recipients at individual time points using the nonparametric unpaired Mann-Whitney U-test. Increases in expression were considered significant if changes were at least two-fold when compared with naive animals, and when the P-value for the difference between syngeneic and allogeneic animals was o0.05. Data are presented as mean±s.e.m. (standard error of the mean). Spearman's r-test was used for correlation analysis of chemokine expression with cytokine expression, pathology and chemokine receptor expression. 
